Expert Interviews

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in part 3 of the Viewpoints Podcast.

Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease in the second part of the Viewpoints Podcast.

In this podcast, Bill B. Trattler, MD, Crystal Brimer, OD, Cynthia Matossian, MD, FACS, and Kelly K. Nichols, OD, MPH, PhD, discuss dry eye disease and the various approaches clinicians can take to treat the disease.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.

At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.

Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.

Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.

Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.

Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."

At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."

Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.

Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"

At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."

Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."

At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"

David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.

Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."

Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."

The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.

Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”

As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.

Jeff Cleland, PhD, CEO of Ashvattha, discusses safety data for an at-home subcutaneous injection option being developed for wet AMD and DME. The anti-VEGF candidate will enter a Phase 2 study later this year.

The study found that if certain forms of nystagmus that are seen in patients, then there is a higher chance of poor binocular visual function, as well as higher interocular suppression.

The study evaluates three separate cases, each which experiences irreversible changes in their corneal structure caused by challenges in getting timely treatment due to various reasons, including insurance, lost to follow up, and the coronavirus pandemic.

The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.

The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.